NewsSource: EClinCloud

Invitation: EClinCloud Invited to Attend the 2022 Clinical Data Management Annual Conference and Share Foundations for More Reliable Clinical Endpoint Assessment

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration




The 2022 Clinical Data Management Annual Conference will be held on November 17–18 in an online format, under the theme "DHT and Clinical Data Management." Invited international and domestic industry experts will address key topics—including discussions on direct data capture technologies and compliance, development standards and applications of clinical outcome assessment (COA), and using information technology to improve the efficiency and quality of data management—to explore the challenges, opportunities, and response strategies brought by technological transformation in the digital era.


Dr. Qin Long, CEO of EClinCloud, has been invited to attend and will deliver an online presentation, looking forward to discussing hot topics of current industry interest with fellow experts.


Session 2: Development Standards and Applications of Clinical Outcome Assessment (COA)

Presentation Time: Thursday, November 17, 14:00–14:30

Presentation Topic: Foundations for More Reliable Clinical Endpoint Assessment - Scale Management and Rater Training


Article illustration
Dr. Qin Long
CEO, EClinCloud


  • Over 16 years of experience in technology applications for the clinical research industry;

  • An innovative and inspiring leader, and a pioneer in promoting and implementing eCOA, EDC, CTMS, and other technology solutions in clinical trial research in China;

  • Previously served as Asia-Pacific head for several international technology companies, leading rapid regional business growth;

  • An entrepreneur driven by academia and science, deeply committed to shaping new models for future clinical trials.



Article illustration
    *Registration: Please visit the SCDM WeChat Official Account for details.



About EClinCloud

EClinCloud is a technology company dedicated to clinical R&D. It provides an integrated, interoperable all-in-one cloud platform for clinical trials—including technology products such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent and solutions such as scale management, linguistic validation, rater training, and data quality analysis—along with clinical trial endpoint assessment technologies across therapeutic areas (including oncology, central nervous system, ophthalmology, and others). By combining cutting-edge technology with life data to build a globally leading, patient-centric SaaS cloud platform supporting clinical evidence, it helps pharmaceutical companies and research institutions in China and abroad improve R&D efficiency and accelerate the market launch of drugs/devices, benefiting countless patients.




Article illustration

Read original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.